Timeline of key milestones and technological advances in neoantigen-based cancer immunotherapy
Year | Milestone | Impact on cancer research | Key technologies | Therapeutic applications | References |
---|---|---|---|---|---|
1950s | Immune recognition of carcinogen-induced tumors | Role of immune system in tumor detection | None | Early understanding | [32, 33] |
1980s | T cell recognition of neoantigens in mice | Cellular immune mechanisms | Murine models | None | [14, 34] |
1990s | Confirmed neoantigen reactivity in mice | Evidence for tumor-specific immune responses | Murine models | None | [35, 36] |
1990s | Neoantigen reactivity in human cancers | Broadened immune detection | Human tumor models | None | [13] |
2000s | Neoantigen reactivity in CD4+ T cells | Identified immune cell responses | Flow cytometry | None | [37] |
2000s | Identified neoantigen-reactive T cells in melanoma patients | Enhanced clinical relevance | Flow cytometry | None | [38, 39] |
2000s | Neoantigen reactivity over shared antigens | Clarified neoantigen advantage | Human tumor models | None | [40] |
2010s | NGS for immunogenic neoantigen identification | Accelerated antigen discovery | NGS | None | [41, 42] |
2010s | NGS for neoantigen-reactive T cells in melanoma | Mapped T cell specificity | NGS, flow cytometry | None | [43, 44] |
2010s | Neoantigen-based adoptive cell therapy in GI cancer | First clinical application | NGS, adoptive cell therapy | GI cancer treatment | [45, 46] |
2010s | Personalized neoantigen vaccines for melanoma | Pioneered patient-specific vaccines | NGS, peptide synthesis | Melanoma treatment | [47, 48] |
2010s | KRAS neoantigen adoptive cell therapy in colorectal cancer | Targeted oncogene mutations | NGS, adoptive cell therapy | Colorectal cancer treatment | [49, 50] |
2010s | Personalized neoantigen peptide and RNA vaccines | Advanced specificity and delivery methods | NGS, RNA technology | Multiple tumor types | [51, 52] |
NGS: next-generation sequencing; GI: gastrointestinal
MMN: Conceptualization, Writing—original draft, Writing—review & editing. OAA: Writing—original draft, Writing—review & editing. SG: Writing—original draft. VB: Writing—review & editing. All authors read and approved the submitted version.
The authors declare there are no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
© The Author(s) 2025.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.